NCT01527305View on ClinicalTrials.gov

A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia

PHASE4CompletedINTERVENTIONAL

Enrollment

212

Participants

Timeline

Start Date

June 22, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Schizophrenia

Interventions

DRUG

Paliperidone palmitate

Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.

Trial Locations (21)

Unknown

Huzhou

Shanghai

Shantou

Suzhou

Wenzhou

Wuxi

Johor Bahru

Kuala Lumpur

Tanjong Rambutan

Busan

Goyang

Gyeonggi-do

Jeonju

Kyounggi

Seoul

Suwon

Douliou City, Yunlin County

Kaohsiung City

New Taipei City

Taichung

Taipei

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT01527305 - A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia | Biotech Hunter | Biotech Hunter